Entering text into the input field will update the search result below

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun. 30, 2022 3:50 PM ETAcumen Pharmaceuticals, Inc. (ABOS) StockBIIBBy: Jonathan Block, SA News Editor

Alzheimer disease

selvanegra/iStock via Getty Images

  • H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise.
  • The firm has a $15 price target (~207% return based on Wednesday's closing price).
  • Unlike

Recommended For You

More Trending News

About ABOS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABOS--
Acumen Pharmaceuticals, Inc.